[logo] HealthTree Foundation
more_vert
chevron_left

ASH 2024

1. Updates from ASH-a-Palooza and Mentoring in Hematology/Oncology | Tax Kourelis, MD | #ASH24 Video

bookmark_border

1. Balancing Treatment Intervals and Quality of Life in Myeloma | Anna Fleischer | #ASH24 Video

bookmark_border

1. IMWG Update: Long-Term Follow-Up, Teclistamab in Relapsed/Refractory #Myeloma | Carlyn Tan, MD | #ASH24 Video

bookmark_border

1. Frailty’s Impact on Outcomes in Older MM Patients Treated with Bispecifics | Nadine Abdallah, MD| #ASH24 Video

bookmark_border

1. Early Relapse Score in Multiple Myeloma | Meral Beksac, MD | #ASH24 Video

bookmark_border

2. Building a Myeloma-Specific Score to Predict CAR-T Therapy Toxicities | Utkarsh Goel MD | #ASH24 Video

bookmark_border

3. Gamma Secretase Inhibition May Boost CAR-T Effectiveness in Some Myeloma | Andrew Portugese | #ASH24 Video

bookmark_border

4. Update on BMS-986393, a GPRC5D #Myeloma CAR-T | Susan Bal, MD | #ASH24 Video

bookmark_border

5. Circulating Tumor Cell As a Biomarker for Outcomes in Myeloma | Luca Bertamini, MD | #ASH24 Video

bookmark_border

6. Myeloma Treatment: Teclistamab Outcomes in Academic vs. Community Settings | Adeel Khan, MD | #ASH24 Video

bookmark_border

7. Myeloma 11 Trial: Carfilzomib Quadruplet Enhances Overall Survival | Charlotte Pawlyn, MD | #ASH24 Video

bookmark_border

8. Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24 Video

bookmark_border

9. ISB 2001 in Relapsed/Refractory #Myeloma: Phase 1 Results | Hang Quach, MD, Cyril Konto, MD | #ASH24 Video

bookmark_border

10. ASH 2024 Wrap-Up: What's next in #Myeloma Treatment | Claudio Cerchione, MD | #ASH24 Video

bookmark_border

11. Outcomes of Teclistamab in RRMM Patients Who Had Prior BCMA-Directed Therapy | Danai Dima | #ASH24 Video

bookmark_border

12. Dara-RVd lite for High Risk Smoldering Myeloma | Omar Nadeem, MD | #ASH24 Video

bookmark_border

13. Treating High-Risk Smoldering Myeloma using CAR-T - CAR-PRISM Study | Omar Nadeem, MD | #ASH24 Video

bookmark_border

14. Loss of CD38 and Resistance Patterns in Myeloma | Benjamin Diamond, MD | #ASH24 Video

bookmark_border

15. Promising Early Data for Improving Talquetamab Effectiveness for MM | Tarek Mouhieddine, MD | #ASH24 Video

bookmark_border

16. Real World Experience of Talquetamab in R/R Myeloma Patients | Ariel Grajales Cruz, MD | #ASH24 Video

bookmark_border

17. Does enhanced genetic testing impact myeloma patients? | Santiago Thibaud, MD | #ASH24 Video

bookmark_border

18. Management and Outcomes of MGRS (Monoclonal Gammopathy of Renal Significance) | Danai Dima | #ASH24 Video

bookmark_border

19. High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma | Urvi Shah, MD | #ASH24 Video

bookmark_border

20. Daratumumab for Patient with High-risk Smoldering Myeloma | Rahul Banerjee | #ASH24 Video

bookmark_border

21. Understanding the Role of Magnesium for Myeloma Patients | Urvi Shah, MD | #ASH24 Video

bookmark_border

22. Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24 Video

bookmark_border

23. Daratumumab + Lenalidomide vs Lenalidomide Maintenance in Myeloma | Laahn Foster, MD | #ASH24 Video

bookmark_border

24. Plasmacytomas are More Genomically Complex than Myeloma in the Bone Marrow | Urvi Shah, MD | #ASH24 Video

bookmark_border

25. Post-CAR-T Driving Restrictions after Week 4 In Myeloma Appear Unnecessary | Rahul Banerjee | #ASH24 Video

bookmark_border

26. 24-hour Urine Testing Does Not Add Value to Myeloma Response Assessments | Rahul Banerjee | #ASH24 Video

bookmark_border

27. Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024 Video

bookmark_border

28. Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024 Video

bookmark_border

29. Social Determinants of Health Impact Myeloma FISH Testing | Amy Pierre, MSN, RN, ANP-BC | #ASH24 Video

bookmark_border

30. Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | Saad Usmani, MD | #ASH24 Video

bookmark_border

31. Understanding the ASH Research Collaborative- COSMIC Study | Saad Usmani, MD | #ASH24 Video

bookmark_border

32. Teclistamab Step-Up Dosing to Prevent CRS in Relapse/Refractory MM | Jeffrey Matous, MD | #ASH24 Video

bookmark_border

33. Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi , PhD & Erin Meermeier, PhD | #ASH24 Video

bookmark_border

34. Ethnicity's Impact on Myeloma Outcomes After Stem Cell Transplant | Frances Cervoni, MD | #ASH24 Video

bookmark_border

35. Combination of Isatuximab, Carfilzomib, Lenalidomide, Dex in Myeloma | Elizabeth O'Donnell | #ASH24 Video

bookmark_border

36. Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD | #ASH24 Video

bookmark_border

37. Inobrodib in Combination with Pomalidomide and Dexamethasone in Myeloma | Emma Searle, MD | #ASH24 Video

bookmark_border

38. Adding Isatuximab to Standard RVD May Improve Outcomes for Myeloma Patients | Elias Mai, MD | #ASH24 Video

bookmark_border

39. Study Shows Promise for Non-Invasive MRD Testing for Myeloma Patients | Dory Abelman PhD(c) | #ASH24 Video

bookmark_border

40. Achieving MRD Negativity: Iberdomide Study for Myeloma Post-AHCT | Natalie Callander, MD | #ASH24 Video

bookmark_border

41. Myeloma Updates: High-Risk Smoldering, MRD, IVIG, and Maintenance | Natalie Callander, MD | #ASH24 Video

bookmark_border

42. Myeloma Patient Experiences with Talquetamab | Jay Hydren, PhD, CSCS | #ASH24 Video

bookmark_border

43. Side Effect Severity & Decision-Making Autonomy in Myeloma | Jay Hydren, PhD, CSCS | #ASH24 Video

bookmark_border

44. Myeloma: Real-World Use of Bispecific Antibodies in Community Oncology | Lisa Herms, PhD | #ASH24 Video

bookmark_border

45. Improving Myeloma Monitoring: Eliminating Sequential Tests | Jean Sebastien Claveau, MD | #ASH24 Video

bookmark_border

46. ICAHT After CAR-T for Myeloma: a Stem Cell Boost Solution | Carolina Schinke, MD | #ASH24 Video

bookmark_border

47. Talquetamab Efficacy & Toxicity in African American Myeloma Patients | Carolina Schinke, MD | #ASH24 Video

bookmark_border

48. Etentamig with Dexamethasone: Promising 2nd Line Therapy for RRMM | Muhamed Baljevic, MD | #ASH24 Video

bookmark_border

49. Combination of Selinexor, Pomalidomide, & Dexamethasone for RRMM | Muhamed Baljevic, MD | #ASH24 Video

bookmark_border

50. CAR-T Therapy (ide-cel) Consolidation for Suboptimal ASCT Responders | Barry Paul, MD | #ASH24 Video

bookmark_border

51. MRD Status in Myeloma: Insights on Changes During Maintenance | Ross Firestone, MD, PhD | #ASH24 Video

bookmark_border

52. KarMMa Study: Immune Profiling in CAR-T Therapy for Myeloma | Bruno Paiva, PhD | #ASH24 Video

bookmark_border

53. Impact of Triplet Therapy for Fit Elderly Myeloma Patients | Maria Victoria Mateos, MD, PhD | #ASH24 Video

bookmark_border

54. Looking Back: Real-World Data on CAR-T and Bispecifics for RRMM | Natalia Neparidze, MD | #ASH24 Video

bookmark_border

55. IVIG and Preventing Infections in Myeloma Patients on Teclistamab | Heloise Cheruvalath | #ASH24 Video

bookmark_border

56. CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24 Video

bookmark_border

57. Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman, MD | #ASH24 Video

bookmark_border

58. Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24 Video

bookmark_border
adjust

59. Genomic Determinants of Resistance to Anti-BCMA CAR-T Therapies in Myeloma | Ciara Freeman | #ASH24 Video

bookmark_border

60. The Unique Power of Whole Genome Sequencing in Multiple Myeloma | Francesco Maura, MD | #ASH24 Video

bookmark_border

61. Belentamab Plus Cyclophosphamide & Dexamethasone in RRMM (ProMMise Study) | Rakesh Popat | #ASH24 Video

bookmark_border

62. MRD Results from Cartitude-4 (Cilta-Cel vs SOC) in RRMM | Rakesh Popat | #ASH24 Video

bookmark_border

63. Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD | #ASH24 Video

bookmark_border

64. Cytomegalovirus Reactivation in Myeloma Patients on Teclistamab | Francesca Cottini, MD | #ASH24 Video

bookmark_border

65. Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD | #ASH24 Video

bookmark_border

66. Real-World Outcomes of Monoclonal Gammopathy of Renal Significance | Francesca Cottini, MD | #ASH24 Video

bookmark_border

67. Improving MGUS Care through Collaborative Models and Community-Based Support | Beth Faiman, CNP, PhD | #ASH24 Video

bookmark_border

68. Belantamab Mafodotin with Carfilzomib, Lenalidomide, & Dex for Early Relapse Myeloma | Shebli Atrash, MD | #ASH24 Video

bookmark_border

69. Optimizing Modakafusp Alfa for Relapsed/Refractory Multiple Myeloma | Shebli Atrash, MD | #ASH24 Video

bookmark_border

70. Talquetamab in Myeloma: Results from HealthTree Qualitative Research | Beth Faiman, CNP, PhD | #ASH24 Video

bookmark_border

71. KRd vs RD: Reducing Progression in High-Risk Smoldering Myeloma | Annemiek Broijl, PhD | #ASH24 Video

bookmark_border

72. New Insights for Amyloidosis in Myeloma | Suzanne Lentzsch, MD | #ASH24 Video

bookmark_border

73. Minority Access & Outcomes with Anti-BCMA CAR T Therapy in Myeloma | Luca Paruzzo, MD | #ASH24 Video

bookmark_border

74. Demonstrating Better Protection with 3 Flu Shots in Myeloma | Craig Hofmeister, MD, MPH | #ASH24 Video

bookmark_border

75. Comparing Outcomes in Younger Multiple Myeloma Patients | Marc Braunstein, MD, PhD | #ASH24 Video

bookmark_border

76. Ethnic Disparities in Myeloma Outcomes | Muzaffar Qazilbash, MD | #ASH24 Video

bookmark_border

77. DREAMM-7 Trial Update: Belantamab's Impact on Myeloma Treatment | Robert Rifkin, MD | #ASH24 Video

bookmark_border

78. MM-6 Trial: In-class transition to Ixazomib in Newly Diagnosed Myeloma | Robert Rifkin, MD | #ASH24 Video

bookmark_border

79. Tri-specific Antibody SAR442257 in RRMM and Non-Hodgkin Lymphoma | Fredrik Schjesvold, MD, PhD | #ASH24 Video

bookmark_border

80. Teclistamab Optec Trial: Prophylactic Toci and Dex during Step-up Doisng | Robert Rifkin, MD | #ASH24 Video

bookmark_border

81. Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD |#ASH24 Video

bookmark_border

82. Using whole genome sequencing to differentiate between low-risk and high-risk smoldering myeloma | Mehmet Samur, PhD | #ASH24 Video

bookmark_border

83. Improvement of Outcomes in High-risk Myeloma (Optimum/Muknine Trial) | Martin Kaiser | #ASH24 Video

bookmark_border

84. Bone Marrow Spatial Signatures Predict Outcomes in R/R Myeloma Patients | Yoshinobu Konishi, MD, PhD | #ASH24 Video

bookmark_border

84. Outcomes in Monoclonal Gammopathy of Renal Significance with Novel Agents | Hira Shaikh and Mehndi Dandwani | #ASH24 Video

bookmark_border

85. Delayed Neutrophil Recovery Following BCMA-Directed CAR-T in Myeloma | Zachary Avigan, MD | #ASH24 Video

bookmark_border

85. Talquetamab in BCMA-Exposed Relapsed/Refractory Multiple Myeloma | Hira Shaikh, MD | #ASH24 Video

bookmark_border

86. MRD Progress in Newly Diagnosed #Myeloma, Quad Induction Therapy and ASCT |Luciano Costa, MD| #ASH24 Video

bookmark_border

87. Trial of Iberdomide, A Novel CELMoD, In Smoldering Multiple Myeloma | Nisha Joseph, MD | #ASH24 Video

bookmark_border

88. Myeloma Patient Preferences: HealthTree Decision-Making Survey | Manni Mohyuddin, MD | #ASH24 Video

bookmark_border

89. Can Mass-Fix Replace Bone Marrow Biopsy? | Angela Dispenzieri, MD | #ASH24 Video

bookmark_border

90. New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates | Paul Richardson, MD | #ASH24 Video

bookmark_border

91. Lovesick: Examining Couples Health During Myeloma Transplant | Ashley Rosko, MD | #ASH24 Video

bookmark_border

92. MRD2STOP: Can multiple myeloma patients stop treatment? | Ben Derman, MD | #ASH24 Video

bookmark_border

Genomic Determinants of Resistance to Anti-BCMA CAR-T Therapies in Myeloma | Ciara Freeman | #ASH24

9 months ago

Lesson Description

Ciara Freeman, MD presents research on identifying genetic features that predict patient responses to CAR-T and bispecific therapies targeting the BCMA antigen in myeloma. By analyzing bone marrow samples through whole genome sequencing, the team aims to personalize treatment plans, focusing on genetic profiles and disease markers to optimize outcomes for patients with different myeloma characteristics.